Molecular biomarkers for cancer immunotherapy
AssigneesMassachusetts Institute of Technology, The General Hospital Corporation
InventorsNir Hacohen, Michael S. Rooney
Life of this patent
Estimating the term…
Abstract
In one aspect, provided herein is a method comprising: (a) (i) determining cytolytic activity in a tumor from the subject; and/or (ii) determining genetic alterations associated with cytolytic activity in the tumor; and (b) administering an immunotherapeutic agent to the subject if (i) cytolytic activity is detected in the tumor and/or (ii) a genetic alteration associated with induction of cytolytic activity, tumor resistance to cytolytic activity and/or suppression of cytolytic activity is detected in the tumor.
Claims12
A method of treating cancer in a patient in need thereof, comprising
- (a) selecting a patient suffering from cancer for immunotherapy by detecting cytolytic activity in tumor tissue from the patient, wherein detecting cytolytic activity comprises measuring cytolytic activity in tumor tissue from the patient by assaying the expression of granzyme A (GZMA) and perforin (PRF1), wherein the measuring comprises sequencing RNA expressed in the tumor tissue, and comprises (i) calculating the log-average of the transcript levels of granzyme A (GZMA) and perforin (PRF1), and (ii) assigning a cytolytic activity (CYT) score to the tumor based on the log average calculated in (i);
- and
- (b) administering to the patient an agent that stimulates the patient's preexisting immune response if the cytolytic activity detected in the tumor is at least two-fold greater than the median value observed among patients diagnosed with the same histological cancer type.
Dependencies are inferred from the claim text.